Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies.
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies.
复制标题
DOI:
10.1007/s00109-014-1161-2
复制
发表时间:
2014-07
影响因子:
4.7
通讯作者:
Trusolino, Livio
中科院分区:
文献类型:
--
作者:
Leto, Simonetta M.;Trusolino, Livio
关键词:
Only approximately 10 % of genetically unselected patients with chemorefractory metastatic colorectal cancer experience tumor regression when treated with the anti-epidermal growth factor receptor (EGFR) antibodies cetuximab or panitumumab (“primary” or “de novo” resistance). Moreover, nearly all patients whose tumors initially respond inevitably become refractory (“secondary” or “acquired” resistance). An ever-increasing number of predictors of both primary and acquired resistance to anti-EGFR antibodies have been described, and it is now evident that most of the underlying mechanisms significantly overlap. By trying to extrapolate a unifying perspective out of many idiosyncratic details, here, we discuss the molecular underpinnings of therapeutic resistance, summarize research efforts aimed to improve patient selection, and present alternative therapeutic strategies that are now under development to increase response and combat relapse.
登录
查看更多内容
影响因子:
28.2
作者:
Bardelli A;Corso S;Bertotti A;Hobor S;Valtorta E;Siravegna G;Sartore-Bianchi A;Scala E;Cassingena A;Zecchin D;Apicella M;Migliardi G;Galimi F;Lauricella C;Zanon C;Perera T;Veronese S;Corti G;Amatu A;Gambacorta M;Diaz LA Jr;Sausen M;Velculescu VE;Comoglio P;Trusolino L;Di Nicolantonio F;Giordano S;Siena S
通讯作者:
Siena S
影响因子:
50.3
作者:
Agus, DB;Akita, RW;Sliwkowski, MX
通讯作者:
Sliwkowski, MX
影响因子:
8.4
作者:
Bokemeyer, Carsten;Van Cutsem, Eric;Koehne, Claus-Henning
通讯作者:
Koehne, Claus-Henning
影响因子:
2.6
作者:
Connolly, K.;Brungs, D.;Epstein, R. J.
通讯作者:
Epstein, R. J.
影响因子:
8
作者:
Brantley, DM;Cheng, N;Chen, J
通讯作者:
Chen, J